Royal Bank of Canada’s Takeda Pharmaceutical TAK Stock Holding History

Royal Bank of Canada’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.1M	Buy	692,900 +78,049	+13%	+$1.29M	﹤0.01%	1990
2026 Q1	$11.4M	Buy	614,851 +60,725	+11%	+$1.07M	﹤0.01%	1820
2025 Q4	$8.64M	Buy	554,126 +64,732	+13%	+$925K	﹤0.01%	2040
2025 Q3	$7.17M	Buy	489,394 +24,543	+5%	+$364K	﹤0.01%	2387
2025 Q2	$7.19M	Buy	464,851 +23,797	+5%	+$352K	﹤0.01%	2281
2025 Q1	$6.56M	Buy	441,054 +43,706	+11%	+$612K	﹤0.01%	2060
2024 Q4	$5.26M	Sell	397,348 -66,712	-14%	-$916K	﹤0.01%	2274
2024 Q3	$6.6M	Buy	464,060 +43,920	+10%	+$623K	﹤0.01%	2068
2024 Q2	$5.44M	Buy	420,140 +21,561	+5%	+$285K	﹤0.01%	2117
2024 Q1	$5.54M	Buy	398,579 +17,524	+5%	+$255K	﹤0.01%	2090
2023 Q4	$5.44M	Sell	381,055 -19,597	-5%	-$278K	﹤0.01%	2173
2023 Q3	$6.2M	Sell	400,652 -26,293	-6%	-$407K	﹤0.01%	1934
2023 Q2	$6.71M	Buy	426,945 +7,541	+2%	+$124K	﹤0.01%	1885
2023 Q1	$6.91M	Buy	419,404 +41,556	+11%	+$662K	﹤0.01%	1833
2022 Q4	$5.89M	Buy	377,848 +3,634	+1%	+$50.8K	﹤0.01%	2013
2022 Q3	$4.85M	Buy	374,214 +5,574	+2%	+$77.5K	﹤0.01%	2098
2022 Q2	$5.17M	Sell	368,640 -21,920	-6%	-$313K	﹤0.01%	2066
2022 Q1	$5.59M	Buy	390,560 +32,527	+9%	+$478K	﹤0.01%	2160
2021 Q4	$4.88M	Sell	358,033 -32,231	-8%	-$452K	﹤0.01%	2394
2021 Q3	$6.39M	Sell	390,264 -12,802	-3%	-$215K	﹤0.01%	2139
2021 Q2	$6.78M	Buy	403,066 +316	+0.1%	+$5.38K	﹤0.01%	2101
2021 Q1	$7.35M	Buy	402,750 +82,754	+26%	+$1.49M	﹤0.01%	1967
2020 Q4	$5.83M	Buy	319,996 +6,881	+2%	+$121K	﹤0.01%	2091
2020 Q3	$5.59M	Buy	313,115 +15,772	+5%	+$287K	﹤0.01%	1930
2020 Q2	$5.33M	Sell	297,343 -105,881	-26%	-$1.9M	﹤0.01%	1899
2020 Q1	$6.12M	Buy	403,224 +143,880	+55%	+$2.61M	﹤0.01%	1662
2019 Q4	$5.12M	Sell	259,344 -19,907	-7%	-$381K	﹤0.01%	2144
2019 Q3	$4.8M	Sell	279,251 -13,385	-5%	-$231K	﹤0.01%	2120
2019 Q2	$5.18M	Buy	292,636 +172,780	+144%	+$3.14M	﹤0.01%	2043
2019 Q1	$2.44M	Buy	119,856 +96,809	+420%	+$1.95M	﹤0.01%	2536
2018 Q4	$388K	Buy	+23,047	New	+$389K	﹤0.01%	3895

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Royal Bank of Canada's TAK Position: Q2 2026 in Review

Royal Bank of Canada increased its Takeda Pharmaceutical (TAK) stake by 13% in Q2 2026, buying an estimated $1.29M and bringing the position to 692,900 shares worth $11.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1990.

Royal Bank of Canada first reported a position in TAK in Q4 2018 and has held it in 31 quarters since. The position peaked at $11.4M in Q1 2026. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Royal Bank of Canada held 692,900 shares of Takeda Pharmaceutical worth $11.1M as of Q2 2026.
Royal Bank of Canada bought 78,049 Takeda Pharmaceutical shares in Q2 2026, an estimated $1.29M.
Takeda Pharmaceutical made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #1990 holding.
Royal Bank of Canada first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 31 quarters since.
Royal Bank of Canada's Takeda Pharmaceutical position peaked at $11.4M in Q1 2026.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.